| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $171.7M | +5.4% |
| SG&A Expense | $47.9M | +4.7% |
| Operating Income | -$209.6M | -0.5% |
| Pre-tax Income | -$155.2M | +25.4% |
| Income Tax | -$15K | -129.4% |
| Net Income | -$155.2M | +25.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $85.7M | -4.1% |
| Current Assets | $777.8M | +27.8% |
| Total Assets | $777.8M | +27.8% |
| Current Liabilities | $58.7M | +8.6% |
| Total Liabilities | $62.5M | -31.0% |
| Stockholders' Equity | $715.2M | +38.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$169.3M | -7.5% |
| Investing Cash Flow | -$143.5M | +59.4% |
| Financing Cash Flow | $309.0M | -24.8% |